Hospital
The Brookdale Hospital Medical Center
The Brookdale Hospital Medical Center was paid $44.03M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoTHE BROOKDALE HOSPITAL MEDICAL CENTER
BROOKLYN, NY 11213
BROOKLYN, NY 11213
33aNPI1487724712assigned 11/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.03M
24GClaims709,321
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#34 of 231
Median peer was paid$561K
This provider vs. median78×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,926 | $244K | |
| 2019 | 76,412 | $3.17M | |
| 2020 | 155,607 | $7.18M | |
| 2021 | 146,952 | $7.94M | |
| 2022 | 80,226 | $7.68M | |
| 2023 | 135,822 | $10.84M | |
| 2024incomplete | 108,376 | $6.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 30,984 | 27,661 | $5.84M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 11% | 25,458 | 8,159 | $5.04M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 9.1% | 33,432 | 21,034 | $3.99M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 22,820 | 19,869 | $3.26M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.9% | 15,208 | 14,080 | $3.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 16,524 | 15,447 | $2.78M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.2% | 17,921 | 15,598 | $2.27M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 3.6% | 53,000 | 5,975 | $1.60M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.3% | 8,280 | 7,516 | $1.45M |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 56,563 | 33,321 | $1.21M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 4,322 | 4,168 | $1.12M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 3,203 | 3,123 | $844K |
323 more codes
| 90834 | Psychotherapy session, about 45 minutes | 1.9% | 5,080 | $833K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 21,900 | $679K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 3,313 | $667K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 12,796 | $606K |
| 99285 | Emergency room visit (most serious) | 1.1% | 2,886 | $494K |
| 80053 | Comprehensive metabolic panel | 1.0% | 24,354 | $450K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,565 | $438K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 4,372 | $405K |
| 80305 | <1% | 12,512 | $377K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,967 | $370K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 845 | $290K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,995 | $288K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,999 | $266K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,690 | $261K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,327 | $238K |
| 81025 | <1% | 6,765 | $211K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,086 | $210K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,717 | $196K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 785 | $184K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 1,315 | $183K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,666 | $169K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 705 | $157K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,061 | $157K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,166 | $151K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 2,026 | $146K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,984 | $120K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 275 | $109K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 487 | $107K |
| 99442 | <1% | 1,626 | $106K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,977 | $97K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 469 | $94K |
| 86480 | <1% | 1,722 | $91K | |
| 99443 | <1% | 1,183 | $88K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,450 | $88K |
| D0120 | Dental checkup, returning patient | <1% | 2,794 | $85K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,235 | $84K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,846 | $84K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 681 | $83K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 390 | $75K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 708 | $70K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 684 | $60K |
| 82962 | <1% | 3,552 | $58K | |
| G2077 | Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code | <1% | 936 | $57K |
| 80061 | Lipid panel | <1% | 5,015 | $56K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,451 | $55K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,597 | $52K |
| 70486 | <1% | 529 | $48K | |
| 99406 | <1% | 894 | $38K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,482 | $38K |
| D1120 | Dental cleaning, child | <1% | 1,205 | $38K |
| 76801 | <1% | 368 | $37K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 726 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 739 | $36K |
| 86850 | <1% | 966 | $36K | |
| 82803 | <1% | 1,628 | $36K | |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 2,156 | $35K |
| 83880 | <1% | 1,755 | $34K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 43 | $34K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 267 | $33K |
| 86900 | <1% | 1,643 | $32K | |
| 86360 | <1% | 1,019 | $31K | |
| 1033F | <1% | 2,002 | $31K | |
| 90732 | <1% | 731 | $30K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,965 | $30K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 324 | $28K |
| 90686 | <1% | 1,172 | $27K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 1,055 | $27K |
| 90715 | <1% | 1,143 | $26K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 817 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,558 | $21K |
| D1110 | Prophylaxis - adult | <1% | 594 | $20K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 226 | $18K |
| 86901 | <1% | 986 | $18K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,136 | $18K |
| 97161 | <1% | 290 | $18K | |
| 86880 | <1% | 707 | $18K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 119 | $16K |
| 88142 | <1% | 520 | $15K | |
| D1206 | Topical application of fluoride varnish | <1% | 652 | $15K |
| 87536 | <1% | 800 | $15K | |
| 90750 | <1% | 108 | $14K | |
| 99051 | <1% | 1,031 | $14K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,446 | $14K |
| 76641 | <1% | 360 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 854 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,050 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,360 | $13K |
| 81001 | <1% | 10,183 | $12K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 883 | $11K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 377 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,802 | $11K |
| 84439 | <1% | 2,676 | $11K | |
| 99441 | <1% | 325 | $10K | |
| 1159F | <1% | 3,019 | $10K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 163 | $10K |
| 73130 | <1% | 720 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 479 | $9K |
| 86769 | <1% | 316 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,822 | $8K |
| 12001 | <1% | 15 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,240 | $8K |
| 85730 | <1% | 5,493 | $8K | |
| 1036F | <1% | 751 | $7K | |
| 84702 | <1% | 3,666 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,489 | $7K |
| 92015 | Determination of refractive state | <1% | 519 | $7K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 254 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,677 | $7K |
| 86706 | <1% | 1,670 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 208 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 364 | $6K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 58 | $6K |
| J3490 | Unclassified drugs | <1% | 2,577 | $6K |
| 96127 | <1% | 3,467 | $6K | |
| 85610 | <1% | 4,807 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,880 | $5K |
| D0274 | Bitewings - four radiographic images | <1% | 252 | $5K |
| 73630 | <1% | 766 | $5K | |
| 80074 | <1% | 383 | $5K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 79 | $5K |
| 86803 | <1% | 1,483 | $4K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 159 | $4K |
| 71250 | <1% | 53 | $4K | |
| 10060 | <1% | 13 | $4K | |
| 87340 | <1% | 1,346 | $4K | |
| 1126F | <1% | 418 | $4K | |
| 99402 | <1% | 90 | $4K | |
| 73560 | <1% | 486 | $3K | |
| 85732 | <1% | 1,008 | $3K | |
| 92133 | <1% | 37 | $3K | |
| 73600 | <1% | 164 | $3K | |
| 82607 | <1% | 643 | $3K | |
| 82043 | <1% | 707 | $3K | |
| 86592 | <1% | 2,200 | $3K | |
| 81003 | <1% | 6,786 | $3K | |
| D0272 | Bitewings - two radiographic images | <1% | 197 | $3K |
| 72100 | <1% | 316 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 136 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 82 | $2K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 89 | $2K |
| 1125F | <1% | 234 | $2K | |
| 83021 | <1% | 101 | $2K | |
| 82728 | <1% | 559 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 28 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,180 | $2K |
| 86780 | <1% | 1,178 | $2K | |
| 86708 | <1% | 343 | $2K | |
| 96367 | <1% | 173 | $2K | |
| 87070 | <1% | 221 | $2K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 32 | $2K |
| 73030 | <1% | 274 | $2K | |
| 83735 | <1% | 3,933 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 817 | $1K |
| 87088 | <1% | 329 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,028 | $1K |
| 86704 | <1% | 408 | $1K | |
| 86701 | <1% | 174 | $1K | |
| H0049 | Alcohol and/or drug screening | <1% | 28 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $1K |
| D9310 | <1% | 38 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 237 | $1K |
| 73110 | <1% | 129 | $1K | |
| 92551 | <1% | 17 | $1K | |
| 90677 | <1% | 12 | $1K | |
| 82570 | <1% | 354 | $1K | |
| 92202 | <1% | 20 | $1K | |
| 86705 | <1% | 357 | $1K | |
| 86593 | <1% | 466 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 874 | $1K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 208 | $1K |
| 82552 | <1% | 1,012 | $986.54 | |
| 73610 | <1% | 235 | $970.17 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 463 | $944.05 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,403 | $938.70 |
| J1815 | Injection, insulin, per 5 units | <1% | 48 | $932.54 |
| 88141 | <1% | 70 | $887.79 | |
| 83690 | <1% | 4,798 | $886.90 | |
| 83615 | <1% | 506 | $886.77 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 43 | $855.78 |
| 73562 | <1% | 38 | $819.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 302 | $815.40 |
| 94060 | <1% | 12 | $805.52 | |
| 90756 | <1% | 71 | $787.78 | |
| 84100 | <1% | 609 | $769.64 | |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $760.18 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 36 | $734.86 |
| 83550 | <1% | 596 | $726.37 | |
| 82746 | <1% | 210 | $718.07 | |
| 99397 | <1% | 34 | $715.91 | |
| 90674 | <1% | 25 | $704.81 | |
| 84484 | <1% | 4,428 | $694.43 | |
| 80320 | <1% | 4,717 | $685.69 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 974 | $674.31 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 850 | $645.41 |
| 84480 | <1% | 261 | $623.94 | |
| 83655 | <1% | 42 | $562.28 | |
| 84436 | <1% | 236 | $557.97 | |
| 90662 | <1% | 44 | $541.19 | |
| 85379 | <1% | 486 | $540.17 | |
| 92134 | <1% | 13 | $540.00 | |
| 11721 | <1% | 12 | $516.04 | |
| J2704 | Injection, propofol, 10 mg | <1% | 701 | $499.22 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 35 | $498.57 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,001 | $441.33 |
| 82550 | <1% | 453 | $440.45 | |
| 73590 | <1% | 27 | $427.24 | |
| 86707 | <1% | 53 | $419.49 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 265 | $409.75 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 996 | $409.24 |
| 83540 | <1% | 250 | $402.29 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,082 | $376.18 |
| 73620 | <1% | 193 | $375.64 | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 13 | $374.26 |
| 86141 | <1% | 59 | $370.90 | |
| G0008 | Administration of influenza virus vaccine | <1% | 46 | $370.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,466 | $369.06 |
| 85660 | <1% | 109 | $355.50 | |
| 81015 | <1% | 3,861 | $348.65 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,194 | $345.72 |
| 85651 | <1% | 283 | $333.53 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 510 | $318.02 |
| 85044 | <1% | 286 | $300.72 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 329 | $296.49 |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $295.74 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 160 | $294.78 |
| 86762 | <1% | 58 | $282.30 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 728 | $279.01 |
| D0330 | Panoramic radiographic image | <1% | 13 | $275.04 |
| 83516 | <1% | 31 | $270.88 | |
| 86765 | <1% | 54 | $261.96 | |
| 90461 | <1% | 80 | $260.82 | |
| 90661 | <1% | 14 | $260.54 | |
| Q3014 | Telehealth originating site facility fee | <1% | 26 | $252.08 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 612 | $229.70 |
| 3008F | <1% | 1,686 | $228.03 | |
| 87081 | <1% | 33 | $216.38 | |
| 85046 | <1% | 324 | $213.06 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 187 | $190.04 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 108 | $186.36 |
| 87077 | <1% | 226 | $172.98 | |
| 82150 | <1% | 402 | $166.85 | |
| 3077F | <1% | 383 | $164.89 | |
| 3074F | <1% | 1,111 | $164.87 | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 12 | $152.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 917 | $151.74 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 213 | $139.31 |
| 82948 | <1% | 1,766 | $137.90 | |
| 87350 | <1% | 52 | $128.97 | |
| 80076 | <1% | 37 | $123.44 | |
| 72040 | <1% | 12 | $121.20 | |
| 83605 | <1% | 822 | $117.42 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 93 | $95.08 |
| 85652 | <1% | 74 | $94.42 | |
| 86140 | <1% | 120 | $73.92 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 40 | $73.16 |
| D9430 | <1% | 12 | $69.08 | |
| 84146 | <1% | 24 | $68.87 | |
| 73120 | <1% | 58 | $64.20 | |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 17 | $62.62 |
| 83001 | <1% | 12 | $62.40 | |
| 73501 | <1% | 25 | $61.44 | |
| 73502 | <1% | 24 | $55.81 | |
| 87040 | <1% | 681 | $55.61 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 737 | $52.54 |
| 82248 | <1% | 163 | $51.92 | |
| 1160F | <1% | 1,753 | $50.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 36 | $47.79 |
| 82977 | <1% | 40 | $45.10 | |
| 87186 | <1% | 18 | $39.54 | |
| 86235 | <1% | 16 | $31.50 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 224 | $30.13 |
| 87400 | <1% | 680 | $27.50 | |
| 74019 | <1% | 41 | $27.21 | |
| 86735 | <1% | 12 | $26.41 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 98 | $26.38 |
| 88304 | <1% | 13 | $25.33 | |
| 86160 | <1% | 18 | $21.22 | |
| 84550 | <1% | 13 | $20.12 | |
| 73564 | <1% | 14 | $20.00 | |
| 96376 | <1% | 13 | $18.59 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 98 | $11.25 |
| 86225 | <1% | 26 | $10.50 | |
| 74018 | <1% | 12 | $10.00 | |
| 73020 | <1% | 12 | $10.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 14 | $6.14 |
| 83930 | <1% | 119 | $6.04 | |
| 82009 | <1% | 157 | $5.50 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 13 | $5.36 |
| 85007 | <1% | 232 | $4.29 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 164 | $2.27 |
| G2089 | Most recent hemoglobin a1c (hba1c) level 7.0 to 9.0% | <1% | 17 | $0.13 |
| 3044F | <1% | 3,518 | $0.07 | |
| 3048F | <1% | 1,843 | $0.03 | |
| 3050F | <1% | 638 | $0.03 | |
| 3079F | <1% | 484 | $0.01 | |
| 3049F | <1% | 944 | $0.01 | |
| 3080F | <1% | 213 | $0.01 | |
| D1330 | 0% | 1,345 | $0.00 | |
| 3017F | 0% | 695 | $0.00 | |
| 1170F | 0% | 218 | $0.00 | |
| 3014F | 0% | 501 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 133 | $0.00 |
| 3075F | 0% | 327 | $0.00 | |
| D1310 | 0% | 1,216 | $0.00 | |
| 3061F | 0% | 308 | $0.00 | |
| 85018 | 0% | 45 | $0.00 | |
| 4010F | 0% | 83 | $0.00 | |
| 4037F | 0% | 161 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 94 | $0.00 |
| 84478 | 0% | 14 | $0.00 | |
| 84132 | 0% | 14 | $0.00 | |
| 73090 | 0% | 12 | $0.00 | |
| 3725F | 0% | 713 | $0.00 | |
| 3078F | 0% | 1,062 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 76 | $0.00 |
| 99080 | 0% | 757 | $0.00 | |
| 88312 | 0% | 23 | $0.00 | |
| 3046F | 0% | 122 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 33 | $0.00 |
| 3062F | 0% | 190 | $0.00 | |
| 3045F | 0% | 37 | $0.00 | |
| 84156 | 0% | 13 | $0.00 | |
| 88302 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFIGUEROA, MICHELLE (SENIOR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Brookdale Hospital Medical Center | Brooklyn, NY | $15.22M |
| Brookdale Family Care Center, INC. | Brooklyn, NY | $8.17M |
| Urban Strategies Brookdale Family Care Center INC | Brooklyn, NY | $2.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.